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Nitric oxideCalorie restriction is one of the most effective nutritional interventions that reproducibly protects against
obesity, diabetes and cardiovascular disease. Recent evidence suggests that even when implemented over a
short period, calorie restriction is a safe and effective treatment for cardiovascular disease. Herein, we review
the effects of calorie restriction on the cardiovascular system as well as the biological effects of resveratrol, the
most widely studied molecule that appears to mimic calorie restriction. An overview of microarray data
reveals that the myocardial transcriptional effects of calorie restriction overlap with the transcriptional
responses to resveratrol treatment. In addition, calorie restriction and resveratrol modulate similar pathways
to improve mitochondrial function, reduce oxidative stress and increase nitric oxide production that are
involved in atherosclerosis prevention, blood pressure reduction, attenuation of left-ventricular hypertrophy,
resistance to myocardial ischemic injury and heart failure prevention. We also review the data that suggest
that the effects of calorie restriction and resveratrol on the cardiovascular system may involve signaling
through the silent information regulator of transcription (SIRT), Akt and the AMP-activated protein kinase
(AMPK) pathways. While accumulating data demonstrate the health beneﬁts of calorie restriction and
resveratrol in experimental animal models, whether these interventions translate to patients with
cardiovascular disease remains to be determined.entre, 458 HMRC, University of
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The World Health Organization (WHO) estimated that 17 million
people die annually from cardiovascular diseases (CVD) globally,
more than from any other cause of death. In the United States, CVD
accounts for 1 in 3 of all deaths [1]. The development of CVD is
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genetics, but also modiﬁable risk factors such as cholesterol levels,
body weight, smoking and blood pressure. Of signiﬁcant concern is
the growing number of individuals who are overweight or obese,
since other diseases such as diabetes have been shown to be caused
by, or associated with obesity [2]. Currently, 150 million individuals in
the U.S. are overweight and 18 million have been diagnosed with
diabetes as well as a further 7 million are predicted to have
undiagnosed diabetes, representing a total of approximately 11% of
the population [1]. This is particularly important in light of the fact
that clinical data have clearly established that obesity and diabetes are
important predictors of cardiovascular morbidity and mortality,
particularly left ventricular hypertrophy (LVH), myocardial infarction,
congestive heart failure and renal failure [3].
Although both lifestyle interventions and a number of drug
therapies exist to treat speciﬁc aspects of CVD, the increasing numbers
of obese and diabetic individuals suggest that the incidence of CVD in
the population will continue to rise. In fact, population studies have
clearly shown that 80% of diabetics die of CVD [3]. As a consequence,
the WHO predicts that by 2030, 24 million people will die annually
from CVD. This represents a 40 percent increase above current levels.
As such, the human as well as the associated economic costs of CVD
highlights the immense beneﬁt of new therapies that could treat
metabolic disorders and at the same time alleviate damage to the
cardiovascular system.
2. Cardiovascular beneﬁts of calorie restriction
Calorie restriction (CR) is the most potent and reproducible
intervention demonstrated to extend lifespan and delay the negative
physiologic consequences of chronic diseases associated with aging
[4]. CR can be broadly deﬁned as restricting the diet of an organism to
fewer calories (20–50%) than ad libitum feeding without altering the
levels of vitamins, minerals and amino acids in order to include all
essential nutrients [4]. CR among organisms as varied as yeast,
nematodes, fruit ﬂies and rodents induced marked increases in
longevity [4] and in pre-clinical testing, has been shown to be
beneﬁcial in a variety of cardiovascular diseases (reviewed in [5]).
Recently, lifelong CR in rhesus monkeys resulted in a 50% reduction in
mortality due to CVD [6]. Although it is not currently known if long-
term CRwith adequate nutrition extendsmaximal lifespan in humans,
we do know that long-term CR without malnutrition results in several
metabolic, hormonal and physiologic adaptations associated with CR
in rodents [5].
Since CR involves several overlapping and mutually dependent
signaling, metabolic, physiologic, genetic and cellular mechanisms, a
complete elucidation of themechanism(s) underlying CR is difﬁcult to
deﬁnitively establish. One feature of CVD is elevated levels of
oxidative damage to proteins, lipids and DNA in the heart and
vasculature. Indeed, cardiac tissue of aged rodents and humans shows
evidence of oxidative damage [7–9] and it has been ﬁrmly established
that this type of damage has a central role in the pathogenesis of
vascular disease [10], ischemic injury [11], LVH [12,13] and heart
failure [12,14]. Importantly, CR activates molecular signals involved in
cellular stress resistance that contribute to the ability of CR to not only
extend life span but to also protect against CVD [6,15]. These include
increased oxidative stress resistance [16,17], reduced production of
reactive oxygen species by cardiac mitochondria [7,18–20], increased
insulin sensitivity [6,21,22], reduced inﬂammation [23–25] and
prevention of cardiomyocyte apoptosis [25].
Over the past decade, several nutrient sensitive molecular signals
and regulators that are involved in the beneﬁts of CR in the heart aswell
as other tissues have been identiﬁed. These include increased
transcriptional activity of the forkhead box O transcription factor [26],
the peroxisome proliferator activated receptor (PPAR)γ co-activator-α
(PGC-1α) [27,28] and the NAD-dependent deacetylase, silent informa-tion regulator of transcription (SIRT) [29–31]. In addition CR modiﬁes
the activities of molecular signaling cascades including activation of the
energy sensing AMP-activated protein kinase (AMPK) [32,33] and the
survival kinase (Akt) [34,35]. However much remains to be determined
with regards to the molecular mechanisms that mediate cellular
adaptations to CR, especially in light of the fact that the mechanisms
for the physiologic responses to CR are not uniform across all tissues
[36–38].2.1. Calorie restriction and vascular function
Long-term CR reduces several risk factors for CVD including
hyperlipidemia, hypertension, abdominal obesity, insulin resistance
and C-reactive protein concentrations [5,6,15,39–42]. In addition, CR
has a number of direct, beneﬁcial effects on the cardiovascular system,
with a major effect on atherosclerosis. Atherosclerosis is an
inﬂammatory disease of the arterial wall that causes accumulation
of oxidized low density lipoproteins and ﬁbrosis in the artery wall that
may ultimately lead to blockages that cause heart attacks and strokes
(see [43] for review). In apolipoprotein E knock-out mice, CR reduced
the size and progression of atherosclerotic lesion formation compared
to ad libitum feeding [44]. The reduction of atherosclerotic lesions by
CR involved reduced circulating low-density lipoprotein cholesterol,
oxidative stress, aortic inﬂammation and ﬁbrosis [44]. The effects of
CR are not restricted to rodent models as CR lowered systemic
inﬂammation in humans, even when it was initiated relatively late in
life [45]. Furthermore, six years of CR lowered several risk factors for
atherosclerosis and reduced the intima-media thickness in the carotid
artery of 18 human volunteers [46], indicating that CR also has
important clinical relevance.
In addition to reducing atherosclerosis, CR has also been shown to
prevent a rise in blood pressure in both genetic and surgical rodent
models of hypertension [16,47–50]. Although the precise mechanism
for this is currently not known, CR may mediate some of its anti-
hypertensive effects via increased bioavailability of the potent
vasodilator, nitric oxide (NO). Consistent with this, it has also been
shown that restricting the calories of both young and aged mice
increases NO production through increased activity of endothelial NO
synthase (eNOS) [17,51,52]. In response to CR, the SIRT1 deacetylase
is activated and regulates the activity of eNOS via the deacetylation of
eNOS on lysines 496 and 506, resulting in higher eNOS activity [17,51].
Conversely, inhibition of SIRT1 prevents endothelium-dependent
vasodilation and reduces NO bioavailability [51], further strengthen-
ing the argument that the NO-mediated effects of CR are mediated via
SIRT1.
In addition to the rodent models described above, data are also
accumulating on the beneﬁcial effects of CR on the vascular system of
humans and non-human primates. For example, monkeys maintained
on a CR regimen also exhibit reduced blood pressure [21]. Moreover,
CR improves the vascular function of healthy non-obese individuals
[40] as well as the endothelium-dependent vasodilation of obese
patients with existing hypertension [53]. In addition to these speciﬁc
studies, a great deal of information has been derived from studying
members of the Caloric Restriction Society (CRS), who voluntarily
restrict their food intake because they believe that they can slow the
aging process. CRS individuals who have CR for an average of 6.5 years
have low blood pressures with an average systolic blood pressure of
100 mm Hg and diastolic blood pressure of 60 mm Hg [54]. This result
was particularly striking given that prior to the initiation of CR, the
average systolic and diastolic blood pressure of CRS individuals were
131 and 82 mm Hg respectively [54], suggesting that CR is a blood
pressure lowering strategy for humans and not just a prevention
strategy. Collectively, these data suggest that long-term CR may be
able to prevent as well as reverse adverse vascular remodeling that
contributes to rises in systemic blood pressure.
Table 1
Cardiovascular effects of calorie restriction on experimental animals.
Strain/animal
model
Age Calories
restricted
Duration References
Improved endothelium-dependent vasodilation
B6D2F1 mice 30–32 months 30% 8 weeks [17]
Fischer 344 rat 7-months 30% 1 week [52]
SHR rat 15 weeks 40% 5 weeks [33]
Reduced blood pressure
Sprague Dawley rat 14 weeks 40% 4 weeks [50]
DOCAsalt sensitive rat ? 50% 5 weeks [49]
SHR rat 13 weeks 40% 8 weeks [48]
SHR rat 15 weeks 40% 5 weeks [33]
Dahl salt-sensitive rat 24 weeks 15% 18 weeks [16]
Rhesus monkey 1-17 years 30% 3 years [21]
Reduced left-ventricular hypertrophy
Sprague Dawley rat ~2 years 35% 2 years [39]
DOCA salt sensitive
rat
50% 5 weeks [49]
SHR rat 17 weeks 50% 8.5 weeks [55]
SHR rat 15 weeks 40% 5 weeks [33]
Dahl salt-sensitive rat 24 weeks 15% 18 weeks [16]
Resistance to ischemia-reperfusion injury
B6D2F1 mice 30 months 40% 6 months [32]
Wistar rat 6 and
24 months
40% 5 and
12 months
[57]
Wistar rat 10 months 45% 8 months [59]
Sprague Dawley rat 20 months 40% 6 months [58]
Fischer rat 12 months 35% 6 months [29]
Fischer rat 12 months 40% 11.5 months [60]
Mice 16 weeks 35% 5 weeks [62]
C57BL6 mice 15 weeks 40% 5 weeks [63]
1479V.W. Dolinsky, J.R.B. Dyck / Biochimica et Biophysica Acta 1812 (2011) 1477–14892.2. Calorie restriction improves cardiac structure and function
Hypertension contributes to cardiac structural remodeling by
causing pathological growth of the myocardium, termed LVH. CR has
been shown to prevent LVH due to hypertension and mechanical
pressure overload [16,39,49,55]. Moreover, similar to the positive
effects of CR on the vasculature, CR also reduces ﬁbrosis in the rat
heart [39], which may also play a role in preventing adverse
remodeling and ultimately improving cardiac function. Consistent
with this latter concept, lifelong CR improved several parameters of
diastolic function in both aged mice [56] and the Dahl-salt sensitive
rat [16], independent of salt intake and reduced the incidence and
severity of spontaneous cardiomyopathies in rats [39] and primates
[6]. In addition, CR prevented the aging-induced decline of diastolic
function and reduced systemic inﬂammation in otherwise healthy
individuals [54], suggesting that CR can also prevent age-mediated
cardiomyopathy. Furthermore, long-term CR improved functional
recovery and reduced injury to the heart following a period of
ischemia [32,57–60]. Although the mechanisms by which this occurs
have not been clearly delineated, lifelong CR reduced reactive oxygen
species and inﬂammation following myocardial infarction [60] as well
as improved mitochondrial function and high-energy phosphate
levels in the heart following reperfusion [59]. Together, these
mechanisms may account for at least some of the cardioprotective
effects of CR. However, it was recently shown that the protection of
the myocardium against ischemia–reperfusion injury by CR required
AMPK activation [32], demonstrating that other signaling pathways
may also be involved. Regardless of the mechanisms, it is clear in
animal models that CR confers cardiac stress resistance and thereby
improves myocardial ischemic tolerance.
2.3. The cardiovascular beneﬁts of short-term calorie restriction
Although the beneﬁts of long-term CR are evident, recent evidence
has shown that short-term CR also has beneﬁts for the cardiovascular
systemof rodents [33,61–64]. Short-termCR involves similar reductions
in calories as long-term CR (30–40%), but is only implemented for
4–5 weeks. Using an ex vivo perfused heart model of ischemia–
reperfusion, short-term CR of normotensive mice improved the
ischemic tolerance of the heart [61–63]. Since impaired cardiac energy
metabolism during ischemia contributes to contractile dysfunction
during reperfusion, the effect of short-term CR on cardiac energy supply
was investigated. Improved functional recovery by CR hearts was
associatedwith increased glucose uptake [62] and oxidation [63] aswell
as elevated cardiac ATP levels following reperfusion, while glycolysis
and fatty acid oxidationwere not signiﬁcantly affected [63]. Therefore, it
appears as though short-term CR maintains energy reserves necessary
to survive an ischemic episode and prevents an imbalance between
glycolysis and glucose oxidation that alters myocardial ionic homeo-
stasis [65].
Although alterations in myocardial metabolism can account for
some of the beneﬁcial effects of short-term CR, there are likely
additional signaling components that regulate other cellular process-
es. Consistent with this, increased phosphorylation of the Akt and
Erk1/2 stress kinases was associated with the prevention of impaired
functional recovery of the heart during reperfusion by short-term CR
[63]. In addition, AMPK activation and an increase in the circulating
levels of the cardioprotective adipokine, adiponectin were required
for the cardioprotective effects of short-term CR since the abrogation
of the adiponectin-AMPK axis prevented the improvement of post-
ischemic recovery in mice subjected to short-term CR [62]. However,
it remains to be determined whether short-term CR also protects
against in vivo myocardial infarction due to left ascending coronary
artery (LAD) occlusion. Intriguingly, short-term CR promotes revas-
cularization of ischemic limbs when CR was initiated in normotensive
rodents prior to vascular injury [64]. This effect of short-term CR wasmediated via an adiponectin-AMPK-eNOS signaling cascade [64], and
suggests that improved vascular function may also play a role in
mediating the beneﬁcial effects of short-term CR on the functional
recovery of the heart following ischemia.
While the preceding reports utilized otherwise young and healthy
rodents to demonstrate that short-term CR was beneﬁcial for the
cardiovascular system, Dolinsky et al. [33] used the spontaneously
hypertensive rat (SHR) model to provide the ﬁrst evidence that short-
term CR was also beneﬁcial for the cardiovascular system of rodents
with modestly elevated blood pressure. Short-term CR prevented a
further rise in blood pressure via signiﬁcantly improved vascular
compliance [33]. In addition, short-term CR prevented the develop-
ment of LVH and diastolic dysfunction in the SHRs [33]. Moreover,
these cardiovascular adaptations to short-term CR were associated
with increased circulating levels of adiponectin, as well as activation
of both AMPK and eNOS in the heart and the arteries of the SHRs [33].
Therefore, short-term CR appears to provide many of the cardiovas-
cular beneﬁts associated with long-term CR (Table 1).2.4. Gene expression proﬁle of calorie restriction
Identiﬁcation of common mechanisms and responses to CR could
provide strategies for the development of potential CR mimetics. To
this end, several studies have utilized microarrays to examine the
effect of CR on the gene expression proﬁle of the mouse heart. Long-
term CR (16 months) reversed 19% of the changes in cardiac gene
expression due to aging and altered the gene expression proﬁle
consistent with preserved fatty acid oxidation, reduced oxidative
damage, and decreased inﬂammation [25]. On the other hand, Dhabi
et al. [66] showed that 8-weeks of CR in younger mice resulted in a
cardiac gene expression proﬁle consistent with improved myocardial
contractility, reduced ﬁbrosis and improved energy generation. A
Table 2
Common molecular targets of calorie restriction and resveratrol in the cardiovascular
system.
Molecular signal Calorie
restriction
Resveratrol
Increased adiponectin [33,62,64] [109,110]
Increased AMP-activated protein kinase [32,33,62,64] [74,78,86,128,134]
Increased Akt [34,63] [85,162,166,172]
Increased endothelial nitric oxide synthase [17,33,51,64] [90–94,100,163]
Increased Mn superoxide dismutase [17,60] [113,115,159,161,166]
Reduced interleukin-6 [16,45] [105,108]
Reduced nuclear factor-KB [23,24,60] [109]
Reduced tumor necrosis factor-α [16,45] [110]
Increased peroxisome proliferator-γ
coactivator-1α
[27,28] [74,77,81]
Increased silent information regulator-1 [17,29–31] [114,161]
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tissue types revealed that only 28 genes shared a common response to
long-term CR in the tissues examined [67]. Nevertheless, it is likely that
in addition todirect effects on theheart the cardiovascular beneﬁts of CR
also involve systemic effects on major organs and tissues. Indeed,
accumulating data show that both life-long and short-term CR have
signiﬁcant physiological beneﬁts for the cardiovascular system through
the reduction of risk factors for CVD as well as through direct effects on
oxidative stress resistance, signaling pathways and gene expression
[5,6,33,62,63,67]. Together, these ﬁndings have clear clinical relevance
since CR is an inexpensive, simple and effective lifestyle modiﬁcation
thatmodiﬁes the onset and improves the outcomes for a range of CVDs.
However, despite the positive effects of CR described above, compliance
to a life-long CR regimen is a major impediment to its utility since the
lifestyle changes required for effective CR need considerable patient
commitment. Therefore, utilizing animal models of short-term CR that
exhibit similar cardiovascular beneﬁts as long-term CR will allow the
more rapid elucidation of the molecular signals and pathways required
for the health beneﬁts of CR. In addition, this approach holds the
promise of future gene therapy and/or pharmacological treatment
strategies that could target pathways to mimic the positive effects of CR
without requiring the discipline of restricting calories. This area of
research is progressing rapidly and the CR mimetic compound that has
received the greatest attention is resveratrol.
3. The cardiovascular beneﬁts of resveratrol
Resveratrol (Resv) is a natural polyphenol produced by plants in
response to environmental stress [68] and is present in many plant-
based foods commonly consumed in our diets, including peanuts,
cranberries, blueberries and grapes. In many instances, nutritional
supplements of Resv are produced from extraction of Resv from the
dried roots of Polygonum cuspidatum (knotweed), which has also been
used in traditional Asian medicine to treat a range of diseases
including cardiovascular disorders [69]. Pharmacological studies
suggest that therapeutic doses of this molecule are non-toxic, easily
absorbed and well tolerated by humans [70]. It is the trans-isomer of
resveratrol that has most of the biological activity as it has been
shown to be a more effective antioxidant than the cis-isomer [71].
Resv is rapidly and efﬁciently absorbed following oral administration,
though its bioavailability is low due to its metabolism to sulfated and
glucoronidated derivates during ﬁrst pass metabolism by the liver
[72,73]. Oral administration of large doses of Resv protects against the
development of diet-induced insulin resistance in aged rodents fed a
high calorie diet [74–78] as well a type 2 diabetic patients [79]. While
many signaling pathways are likely altered by Resv, these metabolic
effect have been reported to be dependent upon activation of SIRT1
[76,77] as well as AMPK [74,78].
Whole genome transcriptional arrays demonstrated that Resv and
CR affected many common genes and pathways in Drosophila [80].
Collectively, several recent studies have demonstrated that Resv and
CR share many of the similar effects on several molecular targets in
the cardiovascular system of mammalian systems (Table 2). These
ﬁndings have received further conﬁrmation by microarray analysis of
the global cardiac gene expression proﬁle of CR mice andmice treated
with Resv. For instance, Barger et al. [81] compared 30-month old
mice fed a diet supplemented with a low-dose of Resv for a period of
16-months to mice that had been fed 25% fewer calories than the
controls. In that study, echocardiography was used to correlate
changes in cardiac function to gene expression. As expected, the CR
intervention reduced the severity of aging-induced diastolic dysfunc-
tion and improvedmyocardial performance [81]. At the same time, CR
prevented 90% of the age-induced changes in cardiac gene expression
[81]. Similar to CR, Resv prevented the decline of cardiac functionwith
age and prevented 92% of the age-induced alterations of gene
expression [81]. Both CR and Resv shared common impacts on theexpression of genes that regulate transcription from RNA, regulate of
chromatin assembly/disassembly and protein ubiquitination, suggest-
ing that a major effect of these interventions is on the transcriptional/
epigenetic state of the cell [81]. However, future work is required to
provide direct molecular evidence that CR and Resv cause alterations
in the epigenome of the cardiovascular system.
Surprisingly, the same gene expression array showed that CR and
Resv had little effect on SIRT1 expression on cardiac genes in aged
mice, or on a number of genes that confer resistance to oxidative stress
[81]. In a follow-up study, these authors used younger mice (treated
from2 to 5 months of age) in a similar experimental design to compare
the effects of CR and Resv on the cardiac gene proﬁle. CR affected 304
genes in the heartwhile Resv affected the expression of 866 genes [82].
Both CR and Resv increased the expression of metabolic genes such as
PGC-1α, uncoupling protein-3 and pyruvate dehydrogenase-4 [82]. In
addition, CR and Resv had signiﬁcant effects on genes that control the
organization of the cytoskeleton and regulate the cellular response to
stress and inﬂammation. Using an approximately 20-fold higher dose
of Resv than the preceding studies, Pearson et al. [83] showed that in
27-month old mice, Resv induced a cardiac gene expression proﬁle
thatwas 64% similar to the proﬁle ofmice fed every other day (another
form of CR), though Resv failed to reverse many of the transcriptional
changes associated with aging. In this study, Resv primarily affected
genes that regulate myocardial contractility, inﬂammation and stress
resistance [83]. Notably, the differentﬁndings of these studies aremost
likely a consequence of the different controls used (ad libitum feeding
versus calories limited to 84 kcal/day), the different types of CR (a 25%
reduction of daily caloric intake versus every other day feeding) and
doses of Resv (4.9 mg/kg/day vs. 167 mg/kg/day). Nonetheless, these
studies demonstrate that, much like CR, the mechanisms responsible
for the beneﬁts of Resv on the CV system appear to be broad and
multifactorial in nature and the response to these interventions appear
to be dependent upon the age of the experimental animal when the
treatment was administered (Tables 1 and 3).
3.1. Resveratrol and vascular function
Resv exerts both acute and chronic effects on the vascular system.
Acute intake of polyphenolic compounds in red wine or grape
extracts, including Resv, has been shown to improve ﬂow-mediated
vasodilation in patients with existing coronary heart disease [84,85].
In addition, both the direct treatment of isolated carotid arteries [86]
and aortic rings [87] with Resv, as well as chronic treatment of rats
with Resv, stimulate endothelium dependent relaxation in aortic rings
from both normotensive and hypertensive rat models [83,88–90]. The
vasodilatory properties of Resv appear to be mediated by increased
bioavailability of NO through the elevation of eNOS expression and
activity [83,90–94]. In addition, Resv reduces the expression of
molecules that promote vasoconstriction such as endothelin (ET)-I
Table 3
Cardiovascular effects of resveratrol administration to experimental animals.
Strain/animal
model
Age Daily dose of Resv Duration References
Improved endothelium-dependent vasodilation
C57BL6 mouse 18 months 167 mg/kg in
the diet
6 months [83]
Wistar rat 14-
16 weeks
50 mg/L in
water
3 weeks [88]
SHR rat 20 weeks 0.448 or
4.48 mg/L
in water
4 weeks [89]
2 kidney 1 clip rat 16 weeks 10 mg/kg I.P.
injection
6 weeks [90]
Reduced blood pressure
Cholesterol-fed
swine
Adult 100 mg/kg in the
diet
11 weeks [122]
Zucker obese rat 23 weeks 10 mg/kg by
gauvage
8 weeks [110]
Fructose-fed rat 11 weeks 10 mg/kg by
gauvage
45 days [93]
Nephrectomized
rat
11 weeks 10 or 50 mg/kg
by gauvage
4 weeks [97]
2 kidney 1 clip
rat
16 weeks 10 mg/kg I.P.
injection
6 weeks [90]
DOCA salt
sensitive rat
11 weeks 1 mg/kg gauvage 4 weeks [125]
Reduced left-ventricular hypertrophy
Nephrectomized
rat
11 weeks 10 or 50 mg/kg by
gauvage
4 weeks [97]
2 kidney 1 clip
rat
16 weeks 10 mg/kg I.P.
injection
6 weeks [90]
DOCA salt
sensitive rat
11 weeks 1 mg/kg by
gauvage
4 weeks [125]
SHR rat 14 weeks 2.5 mg/kg by
gauvage
2 weeks [128]
SHR rat 20 weeks 2.5 mg/kg by
gauvage
10 weeks [127]
Aortic banded rat 10 weeks 2.5 mg/kg by
gauvage
2 weeks [131]
Aortic banded rat 10 weeks 2.5 mg/kg by
gauvage
26 days [132]
Reduced myocardial infarct size following left anterior descending (LAD) coronary
artery occlusion
24 h LAD rat 1 mg/kg by
gauvage
2 weeks prior
to surgery
[151]
24 h LAD rat 10 mg/kg by
gauvage
1 week prior
to surgery
[154]
4 and 30 day
LAD rat
20 mg/kg by
gauvage
2 weeks prior
to surgery
[152]
14 weeks LAD rat 5 mg/kg by
gauvage
4 weeks total [153]
Improved function in heart failure
TO-2 hamster 10 weeks 4 g/kg food 29 weeks [159]
Doxorubicin-treated
rat
10 mg/kg I.P.
injection
7 weeks [162]
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[98]. In hypertensive individuals, hypertrophy of the smooth muscle
cells reduces the compliance of the vessels and it has been shown that
Resv prevents the age-dependent deterioration of aortic elasticity in
mice [83] and this may involve suppression of angiotensin II-induced
hypertrophy of smooth muscle cells [99].
The mechanism for increased NO production has been proposed to
involve the SIRT1 protein deacetylase enzyme. SIRT1 has been shown
to directly deacetylate eNOS at lysine residues, thereby stimulating
NO production [51,100]. Knock-down of endogenous SIRT1 levels
using RNAi attenuated Resv-induced increases in eNOS mRNA and
protein expression [101]. However, AMPK also appears to be involved
in this process as Resv activates AMPK and AMPK is able to directly
phosphorylate eNOS on serine 1177, which increases NO production[102,103]. In fact, pharmacological inhibition of AMPK abolished the
ability of Resv to improve endothelium dependent vasodilation in
aortic rings [87], thus providing compelling evidence of the
importance of AMPK in the Resv-mediated effects on vascular
relaxation.
Resv has also been shown to improve vascular function in hypercho-
lesterolemic rabbits [95]. While these improvements could be partially
explained by Resv-mediated vasodilation, Resv also possesses anti-
atherogenic properties, which may contribute to improved vascular
function. Importantly, since inﬂammation in the arterial wall is a trigger
for the initiation of atherosclerotic lesions, the ability of Resv to inhibit
cyclooxygenase (COX) 2 expression [104] contributes to a reduction of
inﬂammatory molecules such as prostaglandin E2 [104]. In addition, Resv
suppresses the expression of pro-inﬂammatory cytokines such as
interleukins (IL)-6 and IL-8 [83,105–108] and inhibition of nuclear
factor-kappaB [83,109] and tumor necrosis factor-α [83,110]. Moreover,
some of the anti-inﬂammatory effects of Resv in vivo could also be
inﬂuenced by the increased levels of adiponectin in the circulation of Resv
treated rodents [110,111]. However, the role the anti-inﬂammatory
effects of Resvplay in reducing the formationof atherosclerotic lesionshas
yet to be fully explored.
In addition to Resv reducing inﬂammation, Resv also appears to
contribute to atheroprotection through the reduction of oxidative
damage. Indeed, oxidative stress damages the arterial wall triggering
lesion formation aswell as oxidizing lipoproteins in the circulation and
expanding the size of atherosclerotic lesions. Importantly, Resv
scavenges reactive oxygen species [88,112] and Resv increases the
expression of antioxidant enzymes such as superoxide dismutase,
catalase and glutathione peroxidase [112,113], thereby potentially
reducing the formation of atherosclerotic lesions. In addition, SIRT1
expression is reduced in the coronary vessels of aged rats and in
atherosclerotic vessels of individuals undergoing coronary artery
bypass graft surgery [114]. As Resv dose-dependently increases SIRT1
levels and SIRT1 overexpression attenuates mitochondrial oxidative
damage in endothelial cells [114,115], thismay be anothermechanism
by which Resv reduces reactive oxygen species and contributes to
atheroprotection. Moreover, Resv reduces the oxidation of low-
density lipoproteins [116,117] as well as their uptake into the vessel
wall [118,119], while at the same time Resv enhances cholesterol
efﬂux [119,120]. Furthermore, Resv prevents the progression of
atherosclerosis through improved insulin sensitivity [93,121,122], as
well as the reduction of circulating lipids, as observed in obese Zucker
rats [110], db/db mice [121], aged mice [83] and cholesterol-fed
hamsters and swine [103,119,122]. Lastly, Resv may also prevent
thrombosis of atherosclerotic lesions through the inhibition of platelet
aggregation [123,124], providing yet another mechanism by which
Resv can lessen the formation of atherosclerotic lesions.
Vascular dysfunction and atherosclerosis are associated with
higher systemic blood pressure. As mentioned, Resv has been
shown to reduce oxidative stress, angiotensin II concentrations, ET-I
and increase NO concentrations, all of which protect against increased
systolic blood pressure [95–97]. Chronic Resv administration reduces
systemic blood pressure in several animal models of hypertension,
including cholesterol-fed swine [122], obese Zucker rats [110],
fructose-fed rats [93], the DOCA-salt sensitive rat [108,125], the
partially nephrectomized rat [97], two-kidney one-clip hypertensive
rat [90] and in a rat model of pulmonary hypertension [126].
However, in the SHR [89,127,128] and stroke prone-SHR rats [129],
2.5 mg/kg of Resv did not affect the blood pressure. Nevertheless, Resv
did prevent remodeling of the mesenteric artery wall of SHRs that is
typically observed in hypertensive humans and subsequently in-
creased the compliance of these arteries [130]. The differences in the
in vivo effects of Resv in animal models of hypertension are likely a
consequence of different mechanisms for increasing blood pressure in
the various animal models, the dose of Resv administered or the
length of treatment (Table 3). In general, it appears that a minimum
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observe a reduction of blood pressure in most animal models.
Therefore, future studies using higher doses of Resv in SHRs could
reveal that Resv also has anti-hypertensive effects in this rat model
and may thus provide additional evidence that Resv can lower blood
pressure in a wide variety of animal models.
3.2. Resveratrol reduces cardiac hypertrophy
The ability of Resv to prevent elevated blood pressure in animal
models obviously protects the heart from structural remodeling (i.e.
LVH) associated with pressure overload. Indeed, Resv has been shown
to prevent LVH due to lowered systolic blood pressure in a two-kidney
one-clip rat model [90], the DOCA-salt rat model [125] and in partially
nephrectomised rats [97] (Table 3). However, Resv can also prevent
the development of cardiac hypertrophy in the absence of reduced
systemic blood pressure in hypertensive rodents, suggesting that Resv
has direct effects on the growth of the cardiac myocyte. For example,
2-weeks of 2.5 mg/kg Resv treatment prevented LVH in a rat model of
pressure overload due to abdominal aortic banding [131,132] as well
as in SHRs [127,128] without a signiﬁcant effect on blood pressure
(Table 3). However, Resv did not regress LVH due to volume overload
in the rat [132], suggesting that Resv can prevent concentric and not
eccentric hypertrophy. Since LVH is a positive adaptation to exercise
training, it remains to be determined whether Resv has an effect on
the growth of the myocardium in an athlete's heart. Indeed, it may be
that Resv prevents pathological LVH by preventing the activation of
maladaptive cellular processes that are normally not present in
physiological hypertrophy. If this holds true, Resv may be a drug that
speciﬁcally prevents pathological cardiac remodeling without affect-
ing compensatory, physiological remodeling. Therefore, it is impor-
tant to determine the molecular mechanisms involved in the direct
effects of Resv on the growth of the cardiac myocyte.
One key component that contributes to increased cardiac myocyte
size in LVH is enhanced protein synthesis [133]. Importantly, it has
been shown that Resv modulates signaling pathways that regulate
growth and protein synthesis in the isolated cardiac myocyte [134].
For example, Resv inhibited phenylephrine-induced protein synthesis
associated with hypertrophic growth in the cardiac myocyte via
activation of AMPK [134]. Although that study also showed that acute
(1 h) treatment of cardiac myocytes with Resv inhibited Akt, longer
term treatment (24 h) with Resv did not affect Akt activity [134].
Since treatment of Akt1/2 null MEFs with Resv did not block the anti-
growth effects of Resv [134] and in vivo treatment of SHR rats with
Resv for 2 weeks did not alter Akt activity [128], it appears that Akt is
not involved in the anti-hypertrophic effects of Resv. That said, recent
work has suggested that increased Sirt1 activity in transgenic mice
also increases phosphorylation of Akt, which may contribute to
cardiac hypertrophy [135]. However, since Sirt1 is not the only target
of Resv, other pathways may be involved to counteract this effect and/
or Resv may not activate Sirt1 to the same extent as observed in
transgenic mice. With all of these previous ﬁndings in mind, it is
apparent that the role of Akt in the mediating the anti-hypertrophic
effects of Resv is not clearly deﬁned and may be answered using mice
with a cardiac speciﬁc targeted deletion of Akt isoforms.
In agreement with the ﬁndings that AMPK activation can inhibit
hypertrophic growth, itwas recently found thatAMPKdeﬁciencymakes
the heart more sensitive to pro-hypertrophic stimuli [128,136,137].
Furthermore, in the SHR, elevated oxidative stress (speciﬁcally the lipid
peroxidation by-product, 4-hydroxy-2-nonenal (HNE)) reduced AMPK
activity via inhibiting the activity of its upstream activating kinase
(LKB1) [128]. Consistent with the anti-hypertrophic effects of Resv, in
HNE-treated cardiac myocytes Resv prevented inhibition of the LKB1-
AMPK signaling axis and activated signaling pathways that reduce
hypertrophic growth [128]. It was further demonstrated that adminis-
tration of Resv to SHRs reduced cardiac levels of HNE, restored normalLKB1-AMPK signaling, and subsequently reduced LVH in the SHRs [128].
Together, these studies support the notion that LKB1-AMPK signaling is
important for the direct effects of Resv on the cardiac myocyte and that
activation of AMPK by Resv has anti-hypertrophic effects.
Resv may also modulate the response to cardiac hypertrophy via
activation of SIRT deacetylases. For example, activation of SIRT1 by
Resv has been correlated with reduced hypertrophy [138]. However,
the effect of SIRT1 on the growth of the myocardium is dependent
upon its level of expression. Indeed, high levels of SIRT1-transgene
expression (12.5-fold over endogenous levels) promote cardiomyo-
cyte growth [139] and this has been correlated with high levels of
SIRT1 expression in the hypertrophied myocardium [140,141]. In
contrast, lower levels of SIRT1-transgene expression (7.5-fold over
endogenous levels) prevented cardiac hypertrophy.Moreover, whole-
body SIRT1 knock-out mice are resistant to the development of
cardiac hypertrophy and deﬁciency of SIRT1 activity causes hyper-
acetylation of Akt which blocks the phosphorylation and activation of
Akt in the heart [135]. These data suggest that SIRT1 activation is not
involved in the prevention of cardiac hypertrophy by Resv. On the
other hand, SIRT3 overexpression prevented the development of
cardiac hypertrophy via deacetylation LKB1 and activation of the
AMPK signaling pathway [142]. Furthermore, targeted deletion of the
SIRT3 gene promoted the development of cardiac hypertrophy [142].
Taken together, these ﬁndings suggest that the role of SIRTs in the
regulation of cardiac hypertrophy has yet to be ﬁrmly established.
In addition to the effects on protein synthesis, LVH also causes
activation of a fetal cardiac gene expression proﬁle through, in part, the
activation of calcineurin and nuclear factor of activated T-cell (NFAT)
dependent transcription. In response to hypertrophic stimuli, calcineurin
dephosphorylates NFAT and promotes its translocation to the nucleus of
the myocyte where it mediates the transcription of numerous targets
involved in LVH [143]. Notably, Resv inhibitsNFATmediated transcription
in isolated cardiac myocytes at a dose that prevents hypertrophic growth
[134]. However, the mechanism for the inhibition of NFAT by Resv is
unclear. For example, even though at this dose Resv inhibited calcineurin
activity to a similar level as known calcineurin inhibitors (cyclosporine A
and FK506), Resv inhibited NFAT-dependent transcription to a signiﬁ-
cantly greater extent than the calcineurin inhibitors, suggesting that
inhibition of additional signaling mechanisms that regulate NFAT-
dependent transcription are also involved. Indeed, the reduction of
NFAT-dependent transcriptionwas observed at doses that have also been
shown to activate GSK-3β and AMPK [134] and these pathways may also
regulate NFAT. In addition, it was demonstrated that Resv was unable to
inhibit most of the NFAT-dependent transcription in mouse embryonic
ﬁbroblasts lacking AMPK, providing evidence that suppression of the
calcineurin-NFAT pathway is a consequence of AMPK activation [134].
However, whether or not these mechanisms are also important in the
cardiac myocyte has yet to be conﬁrmed.
Since several studies have shown that Resv can prevent cardiac
hypertrophy [127,128,131], using Resv as a therapy for treating elevated
blood pressure could have the additional beneﬁt of improving some of
the cardiac remodeling associated with hypertension. In addition, Resv
has also been shown to prevent the development of other damaging
features of LVH including inﬁltration by inﬂammatory cells [125] and
cardiac ﬁbrosis [108,125]. In addition, Resv treatment of animal models
of LVH was associated with reduced diastolic stiffness [125] and the
prevention of the decline in cardiac contractility observed in both the
DOCA-salt [125] and two-kidney one clip rat [90]. Together, all of these
studies suggest that Resv is a promising molecule that may one day be
used for the treatment of hypertension and/or pathological LVH.
3.3. Resveratrol and ischemia–reperfusion injury
In isolated perfused hearts, the inclusion of Resv in the perfusate
buffer before global ischemia or during reperfusion signiﬁcantly
improved the post-ischemic recovery of function [86,144,145]. In
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ex vivo ischemia–reperfusion without Resv in the perfusate also
improved post-ischemic contractility and coronary ﬂow [146,147].
Moreover, Resv reduced myocardial infarct size in perfused hearts
[145,146,148] and decreased the number of apoptotic cardiomyocytes
via the inhibition of caspase-3 activity and increased Bcl-2 levels [86].
Similar to the observed beneﬁts of CR in ischemia–reperfusion, Resv
has also been shown to precondition the heart through the activation
of survival kinase pathways, which includes post-ischemic activation
of Akt [86]. While there are similarities between Resv and CR in the
post-ischemic setting, it remains to be determined whether Resv also
improves post-ischemic functional recovery through improved glu-
cose oxidation and cardiac energetics in the same manner as CR.
As oxidative stress contributes to ischemic injury, Resv has also
been shown to protect the heart through the reduction of superoxide
production [149], lipid peroxidation products [145,146] and the
activation of antioxidant defenses during ischemia–reperfusion [86].
Some of these studies also demonstrated that cardiac NO production
was required for Resv-induced post-ischemic functional recovery
since L-NAME blocked recovery [147,150]. In rats subjected to
permanent LAD to induce myocardial infarction in vivo, Resv
improved myocardial function, reduced infarct size and reduced the
incidence of ventricular arrhythmias [150–154]. It was also shown
that some of these effects of Resv were mediated by improved
angiogenesis of the myocardium through the induction of pro-
angiogenic factors, including vascular endothelial growth factor
(VEGF) [151,152,154]. Furthermore, Resv improved myocardial
perfusion and the growth of coronary collateral vessels due to
increased VEGF in a swine model of myocardial ischemia [103]. That
said, the role of Resv in angiogenesis is controversial, as several
studies have shown that Resv has anti-angiogenic effects [122,155],
which is a particularly important mechanism for the inhibition of
tumor growth by Resv [156,157]. Once again, differences between the
dose and length of administration of Resv may account for the
different responses of vessel growth to Resv treatment as doses above
30 mg/kg inhibited angiogenesis [122,155–157], whereas doses of
5–10 mg/kg were pro-angiogenic [153,154] and protected against
myocardial infarction. However, hearts from animals with pre-
existing cardiovascular conditions such as hypertension and LVH are
more susceptible to ischemia-reperfusion injury and it remains to be
determined whether Resv is also cardioprotective in these disease
states.
3.4. The role of resveratrol in heart failure
Heart failure arises as a consequence of various heart diseases,
including myocardial infarction, hypertension, and idiopathic dilated
cardiomyopathy [158]. Oxidative stress plays a pivotal role in the
development of chronic heart failure [12] and thus it seems likely that
Resv may be beneﬁcial in this setting. Consistent with this, Resv
reduces ﬁbrosis, prevents ventricular dilatation, preserves cardiac
function and signiﬁcantly improves the survival of hamsters prone to
chronic heart failure [159]. Moreover, Resv enhances MnSOD
expression in the failing myocardium; an effect that requires
accumulation of SIRT1 in the nucleus of the cardiomyocyte [159].
Moreover, Resv has also been shown to have beneﬁcial effects in
doxorubicin-induced heart failure [161,162]. Doxorubicin is a potent
anti-neoplastic agent frequently used in the treatment of cancer.
Despite its efﬁcacy, the use of doxorubicin is limited by the
development of a progressive dilated cardiomyopathy, which can
result in overt heart failure [160]. The generation of reactive oxygen
species by doxorubicin is thought to be the major factor that induces
heart failure, thereby triggering cardiomyocyte cell death [161].
Doxorubicin also reducesMnSOD, catalase and glutathione expression
in the heart [162]. In doxorubicin-treated rats, the addition of Resv to
the treatment regime prevented doxorubicin-induced ﬁbrosis, ven-tricular dilation and the decline in systolic function [162]. Resv also
protects cardiomyocytes from oxidative stress and cell death through
improved mitochondrial function, reduced reactive oxygen species,
and increased expression of anti-oxidant enzymes [161,162]. More-
over, Resv stimulates a SIRT1-MnSOD pathway in doxorubicin-treated
cardiomyocytes, thereby improving cellular survival [161]. As such,
based on the ability of Resv to reduce oxidative stress it is apparent
that Resv is beneﬁcial in the setting of heart failure. However, since
Resv has multiple other effects on the heart, it is also possible that
Resv can improve cardiac function through additional pathways such
as increased oxidative metabolism and improved energy supply.
These concepts need to be tested in a variety of animalmodels of heart
failure in order to fully understand the protective role of Resv in heart
failure.3.5. Resveratrol as a therapy for the cardiovascular complications
associated with diabetes
In rodents, Resv ameliorates hyperglycemia and hyperlipidemia in
streptozotocin (STZ)-induced diabetes [163–166], high-fat diet
induced obesity [74,76–78] and Zucker obese rats [96,110]. Based
on these ﬁndings, it is likely that Resv contributes to cardioprotection
via a reduction of gluco- and lipotoxic damage of the heart and
vasculature in the setting of diabetes. In agreement with this, Resv
reduces vascular wall thickening and collagen deposition in diabetic
rats and it was proposed that Resv mediated this effect through the
activation of Erk1/2 and suppression of nuclear factor-kappaB in the
vessel wall [167]. In addition, Resv reduces lipid peroxidation in
diabetic rats [164] and the expression of the advanced glycation end
product receptor [167]. Moreover, treatment of diabetic rats with Resv
improves the vasorelaxant ability of the aorta [164]. As discussed in
previous sections, many of the effects of Resv in diabetic animals have
been attributed to oxidative stress resistance. While AMPK and SIRT1
were shown to be involved in many of these models [76,115,163],
Resv also upregulates several target genes for the transcription factor
Nrf-2 that also promotes oxidative stress resistance [168]. Whether or
not all of the beneﬁcial effects of Resv in diabetes can be attributed
solely to a reduction in oxidative stress has not been ﬁrmly
established. Regardless of the precise mechanisms, the aforemen-
tioned studies provide clear evidence that Resv is beneﬁcial for several
vascular complications associated with diabetes.
In addition to vascular complications, it is well-documented that
diabetic hearts are more susceptible to ischemia–reperfusion injury
[169]. Because of this, Resv has been tested for its ability to protect the
diabetic heart from ischemia–reperfusion injury. Treatment of obese
Zucker rats with Resv for 3 weeks, followed by 30 min of ischemia and
120 min of reperfusion of the ex vivo perfused heart, improved several
parameters of cardiac function during reperfusion [96]. In addition,
cardiac apoptosis, infarct size and reperfusion-induced ventricular
ﬁbrillation were all reduced by Resv in Zucker rats following
reperfusion [96]. In isolated perfused hearts from STZ-diabetic rats,
Resv also reduced infarct size and improved recovery of function
following 30 min of ischemia [166]. Although the mechanisms by
which Resv protects the diabetic heart from ischemia–reperfusion
injury have not all been elucidated, in both aerobic and ischemia-
reperfused STZ-diabetic rat hearts, Resv has been shown to activate
AMPK and Akt in a non-insulin dependent manner, as well as increase
phosphorylation of eNOS, and promote GLUT4 translocation to the
plasmamembrane [163,166]. Due to this association, it is possible that
these mechanisms could contribute to the protective effects of Resv
via improved glucose utilization. While these studies implicate Akt
and AMPK in promoting increased glucose entry into the heart, it has
also been shown that PI3-kinase is required for the lowering of blood
glucose by Resv [170]. However, whether these molecular changes
contribute to an overall increase in glucose utilization in the diabetic
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Fig. 1. A hypothetical mechanism linking the biological effects of calorie restriction and
resveratrol on nitric oxide production in the cardiovascular system to an integrated
molecular signaling network involving cross-talk between SIRT1 and AMPK. Calorie
restriction lowers the energy state of the cell and raises NAD and AMP levels. Based
upon data from liver cells and tissues [175,180], NAD activates SIRT1 which removes
acetyl groups (Ac) from lysine(K)48 on LKB1 which activates LKB1 by increasing the
association of LKB1 with its STRAD and MO25 subunits. Higher AMP levels and LKB1
activity result in stimulation of AMPK by its phosphorylation (P) on threonine(T)172.
Calorie restriction also raises circulating adiponectin levels which also stimulates LKB1
and AMPK activities. Resveratrol (Resv) mimics the effects of CR on this signaling
network and raises adiponectin levels and increases SIRT1, LKB1 and AMPK activities.
These signaling molecules converge on eNOS which produces nitric oxide(NO) in
response to deacetylation of K496 and K506 by SIRT1 [51] and phosphorylation on
serine(S)1179 by AMPK [102]. Increased NO bioavailability is involved in several
beneﬁcial effects on the cardiovascular system, including endothelium-dependent
vasodilation, reduced blood pressure and improved post-ischemic recovery of cardiac
function.
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future work is needed to explore this possibility
Although increased insulin sensitivity and improved glucose
metabolism may contribute to the ability of Resv to protect the
diabetic heart from ischemia–reperfusion injury, other mechanisms
are likely involved. Indeed, the diabetic heart is more susceptible to
oxidative damage resulting from ischemia–reperfusion than non-
diabetic hearts [171]. As protection from oxidative damage appears to
be a major mechanism of action of Resv, this may also be the case in
the diabetic heart during ischemia–reperfusion. In agreement with
this, cardioprotection by Resv corresponds with increased cardiac
MnSOD activity and a reduction of markers of oxidative damage in
diabetic rats following the reperfusion period [166]. These effects
appeared to also involve NO bioavailability as treatment of rats with
L-NAME abolished the changes in signaling pathways and MnSOD
activity in the STZ-diabetic rats [166]. Although we present oxidative
stress and glucose metabolism as two separate pathways that may be
altered by Resv, previous work has shown that Resv and insulin act
synergistically to improve functional recovery following acute
myocardial infarction ex vivo through activation of Akt, increased
glucose uptake and suppression of superoxide production [172]. As
such, it is likely that Resv exerts its beneﬁcial effects on the ischemic
diabetic heart via multiple pathways. Indeed, Resv treatment of STZ-
diabetic mice restored SERCA2a expression and markedly improved
cardiac function without a signiﬁcant effect on blood glucose levels
[173], providing additional evidence that multiple pathways may be
involved.
3.6. Resveratrol, AMPK, SIRTs and Akt
The prevailing hypothesis for the mechanism by which Resv
mimics CR at the transcriptional level is via the activation of the NAD-
dependent deacetylase SIRT1. However, microarray analysis of global
gene expression proﬁles in the heart seems to indicate that many of
the cardiovascular beneﬁts of CR are achieved by a lower dose of Resv
than is necessary to activate SIRTs [81–83]. Nevertheless, this does not
preclude the possibility that some of the cardiovascular beneﬁts of CR
and Resv could be mediated by SIRTs through deacetylation and
activation of non-nuclear proteins such as eNOS, MnSOD and LKB1
[51,174,175]. Recent reports have also challenged the concept that
Resv is a direct activator of SIRT1 [78,176,177]. Using mouse
embryonic ﬁbroblasts, Chan et al. [134] showed that activation of
AMPK and inhibition of NFAT-mediated transcription by Resv
required the presence of LKB1, which is the upstream activating
kinase of AMPK. Given that both AMPK and SIRTs are responsive to the
energy status of the cell (see [178] and [179] for review), it is not
surprising that both SIRT1 and AMPK appear to share a number of
common molecular targets that regulate similar pathways. Therefore,
it is plausible that considerable cross-talk between these regulators
exists. Indeed, evidence from cell culture studies suggests that
overexpression of SIRT1 reduces the acetylation of LKB1, and
increases the activity of LKB1, while knock-down of SIRT1 expression
increases LKB1 acetylation and reduces LKB1 activity [175]. In
addition, the activity of AMPK was responsive to the changes in
SIRT1 expression and LKB1 acetylation [175]. Consistent with these
ﬁndings, LKB1 acetylation and AMPK activity were downregulated in
the livers of 48 h fasted then 24 h refed rats, demonstrating the
responsiveness of this mechanism to energy status [175]. Further-
more, the ability of Resv to activate AMPK in HepG2 cells as well as
mouse livers required the presence of both SIRT1 and LKB1 [180].
Despite this evidence of a connection between AMPK and SIRT1, it
remains to be established whether this signaling pathway (Fig. 1) is
intact in the heart or vascular system and whether it affects pathways
beyond energy metabolism and extends to the regulation of nitric
oxide production, oxidative stress resistance, inﬂammation and
apoptosis.Several reports have shown that Akt is also activated in the hearts
of calorie restricted and Resv-treated experimental animals (Table 2).
In addition, Akt2 is required for improved insulin-stimulated glucose
uptake by CR in mice [35]. Interestingly, considerable crosstalk exists
between the AMPK and Akt signaling pathways. Insulin or genetic
activation of cardiac Akt reduces the activity of AMPK [181], through
the direct phosphorylation of the AMPK-α subunit on serines-485/491
by Akt [182,183]. In addition, activation of AMPK by metformin and
AICAR is sufﬁcient to reduce the activity and phosphorylation of
downstream targets of Akt [184]. Despite evidence for the inverse
regulation of this signaling axis, elevation of Akt activity by CR and
Resv did not impair AMPK activity. As the treatment of cardiac
myocytes with metformin and AICAR restored AMPK activity even in
the presence of elevated Akt activity [181], we propose that increased
levels of physiologic activators of AMPK (such as AMP or adiponectin)
by CR or Resvmay be sufﬁcient to prevent a reduction of AMPK activity
when Akt is correspondingly activated. That said, it will be important
to clarify the underlying mechanism involved in this process since it
has not been establishedwhether Akt or AMPK activation by CR and/or
Resv is necessary for the stimulation of NO production by eNOS, given
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eNOS. Therefore, we propose that in response to physiologic activators
of Akt such as exercise/IGF-1, activation of Akt is sufﬁcient to stimulate
eNOS-mediated NO production even though AMPK is inactivated by
Akt (Fig. 2). On the other hand, the activation of Akt by CR and Resv
appears to be insulin/IGF-1 independent [186] and may involve
increased expression of Akt binding proteins [187] or modulation of
Akt acetylation [135]. Moreover, during CR or Resv treatment,
physiologic activators of AMPK such as AMP and adiponectin are
sufﬁcient to activate AMPK even in the presence of potentially
inhibitory signals from Akt and consequently both Akt and AMPK
contribute to the stimulation of NO production by eNOS in response to
these interventions (Fig. 2). However, the effect of CR and Resv on the
phosphorylation status of AMPKat serines 485/491 in the heart has not
been reported. While it has been shown that both Akt1 and Akt2 were
not required for the ability of Resv to activate AMPK and inhibit NFAT
[134],micewith cardiac speciﬁc deletion of Akt1 or Akt2 have not been
used to determine whether Akt activity is necessary for cardioprotec-
tion due to CR or Resv treatments.4. Summary
Worldwide, CVD is a major contributor to age-related mortality.
Recent work has demonstrated that CR and Resv share several
beneﬁts for the cardiovascular system of experimental animal models
(Tables 1 and 3). Though some evidence showing that CR has beneﬁts
for the cardiovascular system of people, larger well-controlled clinical
studies are required to demonstrate the efﬁcacy of CR and Resv in
patients with CVD. Interestingly, CR and Resv share several common
molecular targets (Table 2), whichmake Resv an attractive alternative
to gaining the health beneﬁts of CR without restricting caloric intake.
However, in order to identify CR mimetics, future studies are required
to identify the full range of biological processes affected by CR. As
such, a metabolomic analysis of plasma or tissues from experimental
animals subjected to CR would aid the understanding of thebiochemical mechanisms involved in CR. Determination of both the
molecular targets of Resv and whether any of the metabolites of Resv
have biological activities could also lead to the development of new
and more speciﬁc treatments for CVD. That said, given the rising
numbers of obese and diabetic individuals at risk for CVD complica-
tions, the broad spectrum of molecular targets affected by CR and/or
Resv may be even more beneﬁcial as they may treat aspects of CVD as
well as the underlying metabolic disorders. However, their therapeu-
tic potential needs to be evaluated in diabetic populations at risk for
CVD. Despite the lack of clinical data, exciting ﬁndings over recent
years demonstrate that CR and Resv have great promise for the
prevention/treatment of high blood pressure, LVH, myocardial
ischemia, as well as metabolic disorders and provide evidence that
further clinical studies are warranted.Acknowledgements
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